Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]

Value in Health

Volumn 21, Issue 2, 2018, Pages 131-139

  Lakdawalla, Darius N ^a   Doshi, Jalpa A ^b   Garrison, Louis P ^c   Phelps, Charles E ^d   Basu, Anirban ^c   Danzon, Patricia M ^e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cost effectiveness analysis; economics of medical technology; health technology assessment; value of health care

Indexed keywords

ARTICLE; DISEASE SEVERITY; HEALTH CARE; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH EQUITY; HUMAN; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; ADVISORY COMMITTEE; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS; HEALTH CARE DELIVERY; HEALTH CARE POLICY; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; OUTCOME ASSESSMENT; PROCEDURES; UNITED STATES;

ADVISORY COMMITTEES; BIOMEDICAL RESEARCH; BIOMEDICAL TECHNOLOGY; COST-BENEFIT ANALYSIS; DECISION MAKING; DELIVERY OF HEALTH CARE; EFFICIENCY; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 85042255252     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2017.12.007     Document Type: Article

References (54)

1. Gold, M.R., Siegel, J.E., Russell, L.B., Weinstein, M.C., Cost-Effectiveness in Health and Medicine. 1996, Oxford University Press, New York, NY.
2. Neumann, P.J., Weinstein, M.C., Legislating against use of cost-effectiveness information. N Engl J Med 363 (2010), 1495–1497.
3. Neumann, PJ, Using cost-effectiveness analysis to improve health care: Opportunities and barriers. 2005, Oxford University Press, Oxford.
4. Neumann, P.J., Why don't Americans use cost-effectiveness analysis. Am J Manag Care 10 (2004), 308–312.
5. Neumann, P.J., Sanders, G.D., Cost-effectiveness analysis 2.0. N Engl J Med 376 (2017), 203–205.
6. Neumann, P.J., Ganiats, T.G., Russell, L.B., et al. Cost-Effectiveness in Health and Medicine. 2017, Oxford University Press, New York, NY.
7. Garrison, L.P., Pauly, M.V., Willke, R.J., Neumann, P.J., An overview of value, perspective, and decision context–a health economics approach: an ISPOR Special Task Force Report [2]. Value Health 21 (2018), 124–130.
8. Weinstein, M.C., Stason, W.B., Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296 (1977), 716–721.
9. Cookson, R., Willingness to pay methods in health care: a sceptical view. Health Econ 12 (2003), 891–894.
10. Seabury, S.A., Goldman, D.P., Maclean, J.R., et al. Patients value metastatic cancer therapy more highly than is typically shown through traditional estimates. Health Aff (Millwood) 31 (2012), 691–699.
11. Rosen, S., Hedonic prices and implicit markets: product differentiation in pure competition. J Polit Econ 82 (1974), 34–55.
12. Hirth, R.A., Chernew, M.E., Miller, E., et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 20 (2000), 332–342.
13. Lofland, J.H., Pizzi, L., Frick, K.D., A review of health-related workplace productivity loss instruments. Pharmacoeconomics, 22, 2004, 165.
14. Meltzer, D.O., Weckerle, C.E., Chang, L.M., Do people consider financial effects in answering quality of life questions?. Med Decis Making, 19, 1999, 517.
15. Krol, M., Brouwer, W., Sendi, P., Productivity costs in health-state valuations: Does explicit instruction matter?. Pharmacoeconomics 24 (2006), 401–414.
16. Sanders, G.D., Neumann, P.J., Basu, A., et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses in health and medicine: the Second Panel on Cost-Effectiveness in Health and Medicine. J Am Med Assoc 316 (2016), 1093–1103.
17. Grosse, S.D., Krueger, K.V., Mvundura, M., Economic productivity by age and sex: 2007 estimates for the United States. Med Care 47:Suppl. 1 (2009), S94–S103.
18. Hughes, D., Cowell, W., Koncz, T., et al. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health 10 (2007), 498–509.
19. Rosen, A.B., Spaulding, A.B., Greenberg, D., et al. Patient adherence: A blind spot in cost-effectiveness analyses?. Am J Manag Care 15 (2009), 626–632.
20. van Onzenoort, H.A., Menger, F.E., Neef, C., et al. Participation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort study. Hypertension 58 (2011), 573–578.
21. Garrison, L.P., Austin, M.J.F., The economics of personalized medicine: a model of incentives for value creation and capture. Drug Inf J 41 (2007), 501–509.
22. Garau, M., Towse, A., Garrison, L.P., et al. Can and should value-based pricing be applied to molecular diagnostics?. 2012, Research Paper 12/03, Office of Health Economics, London.
23. Goldman, D.P., Gupta, C., Vasudeva, E., et al. The value of diagnostic testing in personalized medicine. Forum Health. Econ Policy 16 (2013), S87–S99.
24. Garrison, L.P., Towse, A., Economics of personalized medicine: pricing and reimbursement policies as a potential barrier to development and adoption. Culyer, T., (eds.) Encyclopedia of Health Economics, 2014, Elsevier, Oxford, UK.
25. Lakdawalla, D., Malani, A., Julian, R., The insurance value of medical innovation. J Public Econ 145 (2017), 94–102.
26. George, B., Harris, A., Mitchell, A., Cost-effectiveness analysis and the consistency of decision-making. Pharmacoeconomics 19 (2001), 1103–1109.
27. Shah, K.K., Severity of illness and priority setting in health care. Health Policy 93 (2009), 77–84.
28. Taylor, M.J., Chilton, S., Ronaldson, S., et al. Comparing increments in utility of health: an individual-based approach. Value Health 20 (2017), 224–229.
29. Rowen, D., Brazier, J., Mukuria, C., et al. Eliciting societal preferences for weighting QALYs for burden of illness and end of life. Med Decis Making 36 (2016), 210–222.
30. Shah, K.K., Does society place special value on end of life treatments?. Round, J., (eds.) Care at End of Life: An Economic Perspective, 2016, Springer, Cham, Switzerland.
31. Lakdawalla, D.N., Romley, J.A., Sanchez, Y., et al. How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Aff (Millwood) 31 (2012), 676–682.
32. Garrison, L.P., Kamal-Bahl, S., Towse, A., Toward a broader concept of value: identifying and defining elements for an expanded cost-effectiveness analysis. Value Health 20 (2017), 213–216.
33. Shafrin, J., Schwartz, T.T., Okoro, T., Romley, J.A., Patient versus physician valuation of durable survival gains: implications for value assessments. Value Health 20 (2017), 217–223.
34. Philipson, T.J., Becker, G., Goldman, D., Murphy, K.M., Terminal care and the value of life near its end. NBER Working Paper No. 15649. 2010, National Bureau of Economic Research.
35. Cook, J.P., Golec, J.H., Vernon, J.A., Pink, G.H., Real option value and path dependence in oncology innovation. Int J Econ Bus 18 (2011), 225–238.
36. Sanchez, Y., Penrod, J.R., Qiu, X.L., et al. The option value of innovative treatments in the context of chronic myeloid leukemia. Am J Manag Care 18 (2012), S265–S271.
37. Snider, J.T., Romley, J.A., Vogt, W.B., Philipson, T.J., The option value of innovation. Forum Health. Econ Policy 15 (2012), 1–19.
38. Culyer, A.J., Bombard, Y., An equity framework for health technology assessments. Med Decis Making 32 (2012), 428–441.
39. Memorial Sloan Kettering Cancer Center. DrugAbacus FAQs. Available from: www.drugabacus.org/faqs. [Accessed December 4, 2016].
40. Institute for Clinical and Economic Review. Overview of the ICER value assessment framework and update for 2017–2019. 2017. Available from: https://icer-review.org/methodology/icers-methods/icer-value-assessment-framework/. [Accessed June 28, 2017].
41. Cookson, R., Mirelman, A.J., Griffin, S., et al. Using cost-effectiveness analysis to address health equity concerns. Value Health 20 (2017), 206–212.
42. Verguet, S., Kim, J.J., Jamison, D.T., Extended cost-effectiveness analysis for health policy assessment: a tutorial. Pharmacoeconomics 34 (2016), 913–923.
43. Phelps, C.E., Lakdawalla, D.N., Basu, A., Drummond, M.F., Towse, A., Danzon, P.M., Approaches to aggregation and decision making – a health economics approach: an ISPOR Special Task Force Report [5]. Value Health 21 (2018), 146–154.
44. Asaria, M., Griffin, S., Cookson, R., Distributional cost-effectiveness analysis: a tutorial. Med Decis Making 36 (2016), 8–19.
45. Baltussen, R., Jansen, M.P.M., Bijlmakers, L., et al. Value assessment frameworks for HTA agencies: the organization of evidence-informed deliberative processes. Value Health 20 (2017), 256–260.
46. Morton, A., Aversion to health inequalities in healthcare prioritisation: a multicriteria optimisation perspective. J Health Econ 36 (2014), 164–173.
47. Garrison, L., Mestre-Ferrandiz, J., Zamora, B., The value of knowing and knowing the value: improving the health technology assessment of complementary diagnostics. 2016, White Paper, Office of Health Economics and EPEMED, London.
48. Chang, H.F., Patent scope, antitrust policy, and cumulative innovation. Rand J Econ 26 (1995), 34–57.
49. Blume-Kohout, M., Drug development and public research funding: evidence of lagged effects. 2009, Working Paper, RAND Corporation, Santa Monica, CA.
50. Williams, H., Intellectual property rights and innovation: evidence from the human genome. J Polit Econ 121 (2013), 1–27.
51. National Institute for Health and Care Excellence. Appraising Life-Extending, End of Life Treatments. 2009, National Institute for Health and Care Excellence, London.
52. Persson, U., Value based pricing in Sweden: Lessons for design?. 2012, OHE Seminar Briefing No. 12, Office of Health Economics, London.
53. Scottish Medicines Consortium. SMC modifiers used in appraising new medicines. Available from: www.scottishmedicines.org.uk. [Accessed January 16, 2017].
54. Sullivan, S.D., Yeung, K., Vogeler, C., et al. Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm 21 (2015), 269–275.